Viking Therapeutics CEO equity grant and tax sale

Viking Therapeutics, Inc. reported that President & CEO Brian Lian acquired 221,667 shares of common stock on July 28, 2026 through the vesting of a performance RSU award granted January 3, 2023.

Rhea-AI Filing Summary

Viking Therapeutics, Inc. reported that President & CEO Brian Lian acquired 221,667 shares of common stock on July 28, 2026 through the vesting of a performance RSU award granted January 3, 2023. On July 29, 2026, 148,517 shares were automatically sold at a weighted-average $33.3153 per share solely to satisfy tax withholding obligations.

Insider Trade Summary

Net Seller: 148,517 shares

Net Sell 2 txns

Insider Lian Brian

Role President & CEO

Sold 148,517 shs ($4.95M)

Type	Security	Shares	Price	Value
Sale	Common Stock, par value $0.00001 per share F2, F3	148,517	$33.3153	$4.95M
Grant/Award	Common Stock, par value $0.00001 per share F1	221,667	$0.00	$0.00

Holdings After Transaction: Common Stock, par value $0.00001 per share — 2,572,441 shares (Direct)

Footnotes (3)

1. F1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.
2. F2. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.
3. F3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.

Key Figures

RSU vesting shares: 221,667 shares Tax-withholding sale shares: 148,517 shares Weighted-average sale price: $33.3153 per share +2 more

5 metrics

RSU vesting shares 221,667 shares Shares acquired by CEO from performance RSU vesting on July 28, 2026

Tax-withholding sale shares 148,517 shares Shares automatically sold on July 29, 2026 to satisfy tax withholding

Weighted-average sale price $33.3153 per share Weighted-average price for tax-withholding share sale on July 29, 2026

Sale price range $32.82 to $33.77 per share Range of prices for multiple sale transactions covering tax obligations

Vested RSU portion 33.33% Portion of performance RSU award that vested on July 28, 2026

Key Terms

performance restricted stock unit award, tax withholding obligations, weighted average price, non-discretionary basis

4 terms

performance restricted stock unit award financial

"subject to a performance restricted stock unit award that was granted on January 3, 2023"

tax withholding obligations financial

"solely to satisfy certain tax withholding obligations in connection with the issuance of shares"

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

non-discretionary basis financial

"automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider equity activity did Viking Therapeutics (VKTX) report for CEO Brian Lian?

Viking Therapeutics reported that CEO Brian Lian acquired 221,667 shares of common stock from a performance RSU vesting on July 28, 2026, and 148,517 shares were automatically sold the next day solely to cover tax withholding obligations related to that vesting.

How many Viking Therapeutics (VKTX) shares did Brian Lian receive from the RSU vesting?

Brian Lian received 221,667 shares of Viking Therapeutics common stock on July 28, 2026. These shares came from a performance restricted stock unit award that was originally granted on January 3, 2023, after achievement of a specified non-financial performance goal.

Why were 148,517 Viking Therapeutics (VKTX) shares sold on July 29, 2026?

The 148,517 shares sold on July 29, 2026 were automatically sold on a non-discretionary basis solely to satisfy tax withholding obligations arising from the issuance of shares upon vesting of the performance RSU award, rather than a discretionary open-market sale by the CEO.

At what price were the Viking Therapeutics (VKTX) CEO’s shares sold?

The reported sale used a $33.3153 weighted-average price per share. According to the disclosure, the 148,517 shares were sold in multiple transactions at prices ranging from $32.82 to $33.77 per share, inclusive, to cover tax withholding.

What portion of the Viking Therapeutics (VKTX) performance RSU award vested?

On July 28, 2026, 33.33% of Brian Lian’s performance restricted stock unit award vested. The vesting occurred upon achievement of a non-financial performance goal specified in the award granted on January 3, 2023, leading to issuance of 221,667 common shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/29/2026 - 08:07 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lian Brian

(Last) (First) (Middle)

C/O VIKING THERAPEUTICS, INC.

9920 PACIFIC HEIGHTS BLVD, SUITE 350

(Street)

SAN DIEGO CALIFORNIA 92121

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Viking Therapeutics, Inc. [ VKTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/28/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.00001 per share	07/28/2026		A		221,667(1)	A	$0	2,720,958	D
Common Stock, par value $0.00001 per share	07/29/2026		S		148,517(2)	D	$33.3153(3)	2,572,441	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The reported securities were subject to a performance restricted stock unit award that was granted on January 3, 2023, 33.33% of which vested on July 28, 2026 upon the achievement of a non-financial performance goal.

2. These shares were automatically sold on a non-discretionary basis solely to satisfy certain tax withholding obligations in connection with the issuance of shares upon the vesting of certain shares of common stock subject to the performance restricted stock unit award described in Footnote 1.

3. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.82 to $33.77, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in the this footnote.

	/s/ Michael Morneau, as Attorney-in-Fact	07/29/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)